* Sees Q4 Ampyra sales of $55.7 mln
* Sees FY gross sales of $141.4 mln vs est $185.12 mln
* Shares up as much as 9 percent
Jan 10 Acorda Therapeutics Inc (ACOR.O)
forecast better-than-expected quarterly sales view for its drug
to treat walking difficulties in patients with multiple
sclerosis, sending its shares up 9 percent.
The pharmaceutical company said it expects fourth-quarter
sales of $55.7 million from its key drug Ampyra.
In November, Acorda had warned of a decrease in sales for
Ampyra, as the number of new patients starting on the drug,
which was launched in March, would no longer be augmented by
patients from the backlog. [ID:nSGE6A00FY]
Analysts have, since then, revised fourth-quarter sales
expectation of Ampyra to $44-$50 million.
The Hawthorne, New York-based company also said it sees
gross sales of $141.4 million for the year.
Analysts, on an average, were expecting revenue of $185.12
million for the year, according to Thomson Reuters I/B/E/S.
Acorda shares, which have risen 10 percent since its
warning on lower Ampyra sales, were up 7 percent at $29.48 on
Monday on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Roshni